call for abstracts2 0 1 3 A C R / A R H P

Abstract Submission Deadline: tuesday, June 25, 2013, Noon Eastern time

GUIDElINEs

the latest in RheumatologyDiscover

S a n D i e g o ‘ 1 3

Visit www.ACRannualmeeting.org for more annual meeting information.

2

PrEsENt YoUr abstract at tHE 2013 acr/arHP aNNUal MEEtINGThe American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) invite you to submit an abstract and take advantage of the opportunity to have your work peer-reviewed by experts in the field.

Each year, the annual meeting draws thousands of abstracts submitted by rheumatologists and health professionals from around the world. If accepted, your abstract will be published in the Arthritis & Rheumatism journal (online only) and displayed in an international venue.

This is your complete guide for submitting an abstract to the 2013 ACR/ARHP Annual Meeting. It is recommended that you read this guide prior to the submission process.

tHIs YEar• To better meet your needs, select abstract categories have

been modified.

• A new ACR basic science abstract category entitled “Pain: Basic Aspects” has been introduced.

• New Poster Hall Hours are 8:30 am - 4:00 pm, Sunday, October 27 – Tuesday, October 29.

• There will be an unopposed poster presentation hour from 10:00 - 11:00 am during each poster session.

• The ACR will promptly remove and recycle all posters not picked up by 5:00 pm each day.

• ARHP abstracts will be incorporated with ACR abstracts by topic area in the poster hall.

aboUt tHE aNNUal MEEtINGThe 2013 ACR/ARHP Annual Meeting is the premier educational event for physicians, health professionals and scientists who treat those with or at risk for arthritis, rheumatic and musculoskeletal diseases.

The annual meeting is a forum for physicians and health professionals to receive the most relevant and latest developments in rheumatology.

Discover the latest in Rheumatology

See you in San Diego, California at the 2013 ACR/ARHP Annual Meeting. Abstract submission guidelines and instructions are available at www.ACRannualmeeting.org.

Visit www.ACRannualmeeting.org for more annual meeting information.

3

tablE of coNtENts Eligibility ................................................................................................ Page 4

Submitting an Abstract ........................................................................... Page 4

ACR Call for Abstracts ............................................................................ Page 5

Basic Research & Clinical Research Conferences Abstracts .................... Page 5

ARHP Call for Abstracts .......................................................................... Page 6

Students, Residents and Fellows-in-Training ......................................... Page 6

Disclosure Policy ..................................................................................... Page 6

Abstract Review and Notification ........................................................... Page 7

Presentation Format .............................................................................. Page 8

Permissions ............................................................................................ Page 9

Embargo Policy ...................................................................................... Page 9

Publication ............................................................................................ Page 11

Revisions .............................................................................................. Page 11

Withdrawals ........................................................................................ Page 11

Presenting Author Responsibilities ....................................................... Page 12

2013 ACR and ARHP Abstract Categories ............................................ Page 12

ACR Late-breaking Abstracts ............................................................... Page 14

Important Dates .................................................................................. Page 15

Please read this entire guide prior to beginning the submission process to review the guidelines and rules that apply to abstract submissions.

Visit www.ACRannualmeeting.org for more annual meeting information.

4

ElIGIbIlItY 1. Abstracts describing original basic science and clinical work

related to the broad area of rheumatic diseases may be submitted.

2. An abstract is ineligible for consideration if it reports work that has been accepted prior to the ACR/ARHP submission deadline of Noon Eastern Time on Tuesday, June 25, 2013, for publication as a manuscript.

3. The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.

4. By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation at the annual meeting in San Diego, CA.

5. Case reports are not considered appropriate and will not be reviewed.

6. If the abstract reports results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.

7. Abstracts submitted for the late-breaking category cannot be submitted to another category.

8. Abstracts submitted for the ARHP program may not be dually submitted to the ACR program.

9. You do not have to be a member of the ACR or ARHP to submit an abstract.

10. Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

sUbMIttING aN abstract All abstracts must be submitted using the online submission site. The 2013 ACR abstract categories are listed on page 12.

For technical assistance regarding the abstract submission site, contact The Conference Exchange technical support at (401) 334-0220 or via e-mail at acr@confex.com between 8:30 am and 6:00 pm, Eastern Time, Monday through Friday. For general inquiries regarding abstract submission, email abstracts@rheumatology.org or call (404) 633-3777.

abstract format The abstract limit is 2,750 characters, which excludes the title, names of authors/co-authors, authors’ affiliations, spacing and disclosures. However, imported tables and graphics will decrease the character count by 250 characters from the total limit allowed. Abstracts exceeding the character limit will be considered “incomplete.” Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for consideration.

titleTitles should be brief, clearly indicating the nature of the presentation. When entering the abstract title online, use mixed case (do not use all caps) and do not put a period at the end of the title. Enter the title in the “title” field only and do not enter the title in the body of the abstract.

Example: This is a Properly Formatted Abstract Title

Use of acronymsPlease refrain from using acronyms in your abstract titles as the ACR/ARHP will no longer publish acronyms that are listed in the titles of abstracts. Acronyms may remain in the body of the abstract and in the author list.

authors Do not list authors or commercial relationships in the body of the abstract. Please consult with your co-authors on how they would like their names to appear prior to the submission of the abstract. You may list no more than 25 individual authors for each abstract. All authors must disclose any relevant financial relationship(s) at the time of abstract submission.

See the abstract disclosure statement section on page 6, for additional author identification instructions.

content Omit all names and geographical references in the body of the abstract. Organize content as follows:

• background: Background or Statement of Purpose

• Methods: Methods, materials and analytical procedure used

• results: Summary of the results in sufficient detail to support conclusion

• conclusion: Conclusions reached (do not state “results will be discussed”)

Discover the latest in Rheumatology

Go to ACRannualmeeting.org to get started. The 2013 ACR abstract categories are listed on page 12.

Visit www.ACRannualmeeting.org for more annual meeting information.

5

Use of Product Names The non-proprietary (generic/scientific) name can be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content. Failure to comply will result in disqualification of your submission.

Abbreviations Use standard abbreviations. Place special or unusual abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.

tables and Graphics Specific information regarding acceptable graphic files is included on the online submission site. Microsoft PowerPoint® files are not accepted.

acr call for abstracts The program for the ACR Annual Meeting includes content related to the clinical practice and teaching of rheumatology and the basic and translational science which contribute to the understanding of disease pathogenesis, the mechanisms and efficacy of therapeutics and the delivery of health care to patients with musculoskeletal and rheumatic disease.

sUbMIssIoN DEaDlINE: Tuesday, June 25, 2013, Noon Eastern Time – no exceptions. You will not be able to access the submission site after Noon Eastern Time on Tuesday, June 25.

sUbMIttING aN abstract Go to the abstract online submission site to get started. The 2013 ACR abstract categories are listed on page 12.

abstract Processing fee A $70 processing fee must accompany each ACR abstract. The ACR accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees must be in U.S. funds and are non-refundable – no exceptions.

basIc rEsEarcH aND clINIcal rEsEarcH coNfErENcEs abstracts Young investigators with less than six years of experience may also submit an abstract that has been submitted to the ACR general program, to the Basic Research Conference or Clinical Research Conference for consideration. Young investigators will be required to check a box during the submission process to indicate if they want to have their abstract considered for inclusion in either conference.

Acceptance to the ACR program is a prerequisite for consideration by the Basic Research Conference or Clinical Research Conference, and acceptance to either conference does not remove the abstract from the ACR general program.

sUbMIssIoN DEaDlINE: Tuesday, June 25, 2013, Noon Eastern Time – no exceptions. You will not be able to access the submission site after the deadline.

Eligibility • Investigators with less than six years of experience are

eligible to submit an abstract to the Basic Research Conference or Clinical Research Conference.

• Abstracts must also be submitted to the ACR general program.

• Abstracts not accepted to the Basic Research Conference or Clinical Research Conference program are still eligible for consideration in the ACR general program.

acr basic research conference criteria Abstracts should be those broadly related to concepts of epigenetics, and the range of associated molecular mechanisms. Abstracts related to the development of rheumatic diseases, such as rheumatoid arthritis, lupus, vasculitis, osteoarthritis and spondylarthropathies, and how these inherited changes affect cartilage, bone, periarticular tissues as well as disease-characteristic innate and adaptive immune abnormalities are also encouraged.

Visit www.ACRannualmeeting.org for more annual meeting information.

6

acr clinical research conference criteria Abstracts should be those broadly related to the field of pre-clinical and early autoimmune rheumatic diseases. For example, abstracts pertaining to recent research on genetics, epigenetics, biomarkers such as cytokines and autoantibodies, risk prediction or screening in populations, or early treatment to abrogate disease development are applicable. Abstracts related to pathogenesis of systemic rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, spondylarthropathies, and psoriatic arthritis, in particular in predicting disease susceptibility and detecting its earliest signs are also encouraged.

abstract Processing fee There is no additional fee to have your abstract considered for the Basic Research or Clinical Research Conferences.

format Abstracts may be selected for oral or poster presentation, and author should be prepared to present in either format. Accepted abstract presentations will be held during the pre-conference courses on Friday, October 25 and Saturday, October 26.

arHP call for abstracts The ARHP program is planned to reflect the needs and interest of healthcare professionals who share an interest in rheumatology-related issues by providing a forum to address issues of professional significance with a multidisciplinary audience.

sUbMIssIoN DEaDlINE: Tuesday, June 25, 2013, Noon Eastern Time – no exceptions. You will not be able to access the submission site after the deadline.

sUbMIttING aN abstract Go to the online submission site to get started. The ARHP abstract categories are listed on page 14.

abstract Processing fee A $40 processing fee must accompany each ARHP abstract. The ARHP accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees must be in U.S. funds and are non-refundable – no exceptions.

for stUDENts, rEsIDENts aND FELLOWS-IN-TRAINING Submission by Students, Residents and Fellows-in-Training as Presenting Authors:

The ACR encourages the submission of abstracts by presenting authors who are pre-doctoral and post-doctoral students, residents, medical students or fellows-in-training. Please check the box on the submission site to indicate your training status.

The Rheumatology Research Foundation Abstract award The Rheumatology Research Foundation offers award opportunities for medical students, residents, and pediatric rheumatology fellows who submit an abstract for the 2013 ACR/ARHP Annual Meeting by the June 25 submission deadline. Award recipients will receive a cash award plus reimbursement of travel expenses to attend the meeting. Acceptance of an abstract does not automatically enroll or guarantee receipt of a Foundation Abstract Award. Visit Foundation’s Abstract Awards or call (404) 633-3777, ext. 318 for deadlines and complete award details.

DIsclosUrE PolIcY It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control content disclose all relevant relationships with any commercial interest if the relationship is financial and occurred within the past 12 months. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR’s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content.

Discover the latest in Rheumatology

Disclosures collected at the time of submission will be published in the scientific program, abstract supplement and on the ACR website.

ENEB

RO12

0 AC

R JA

AD

TRIM

: 8.3

75"

x 10

.875

"

BLEE

D: .1

25"

LIVE

: 6.8

75"

x 9.

875"

JF

7/1

7

When you have decided a biologic is the next step

Choose ENBREL

for appropriate moderate

to severe RA patients

Indication

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the

progression of structural damage, and improving physical function in patients with moderately to severely

active RA. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

Important Safety Information

ENBREL has been shown to increase the risk of serious infections leading to hospitalization or death,

including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and

infections due to other opportunistic pathogens, and should be discontinued if a patient develops a serious

infection or sepsis. Test for latent TB (if positive, start treatment for TB prior to starting ENBREL) and

monitor for active TB during treatment. Lymphoma and other malignancies, some fatal, have been reported

in children and adolescents treated with tumor necrosis factor (TNF) blockers, including ENBREL.

Please see additional Important Safety Information and Brief Summary of Prescribing Information on the

adjacent pages.

TEMPO was a 3-year, multicenter, double-blind, clinical trial of 682 patients with moderately to severely active RA (mean disease duration: 7 years), who had an

inadequate response to at least 1 DMARD excluding MTX. At baseline: patients were ≥18 years of age, MTX-naïve, had an ESR ≥28 mm/hr or CRP ≥20 mg/L, and were

in ACR functional class I, II, or III.1,2

Call ENBREL Support™ after you prescribe:

1-888-4ENBREL

www.enbrel.com/rheumpro

ENBREL provided rapid and sustained efficacy

in patients with moderate to severe RA

ACR 20 Responses at Week 2, Year 1, and Year 3 (NRI) were1:

44%, 75%, and 52% for ENBREL + MTX*

19%, 59%, and 33% for MTX only

*P<0.001 vs MTX at all timepoints

NRI=Nonresponder imputation

Visit us at

booth 707

B:11.125 in

B:8.625 in

T:10.875 in

T:8.375 in

S:9.875 in

S:6.875 in

programB O O K

Pre-meeting Courses: November 9-10, 2012

oPening leCture and awards, oPening event: November 10, 2012

sCientifiC sessions: November 10-14, 2012

Visit www.ACRannualmeeting.org for more annual meeting information.

7

abstract Disclosure statementAll authors must disclose any relevant financial relationship(s) at the time of abstract submission. Examples include, but are not limited to the following:

1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan

2. Research grants

3. Employment (full or part-time)

4. Ownership or partnership

5. Consulting fees or other remuneration

6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson

7. Receipt of royalties

8. Speakers’ bureau

9. Other

None: has no relevant financial relationship to disclose

Disclosures collected at the time of submission will be published in the scientific program, abstract supplement and on the ACR website. Abstracts will not be accepted without proper completion of the conflict of interest/disclosure section on the abstract submission form. Failure to disclose correctly may lead to corrective action as deemed appropriate by the ACR or ARHP leadership. The abstract review process is blinded; therefore, the disclosure information you provide will not influence the review of your abstract.

Involvement of Individuals Not listed as authors Names of all individuals who had a substantial role in the study or abstract preparation who are not included in the list of authors must be disclosed. For each individual, please describe the activity or activities, the reason the individual is not listed as an author, and the manner in which the individual’s participation is being disclosed to the learner, (e.g., studies design, acquisition of data, analysis and interpretation of data, abstract preparation, statistical analysis or other). These disclosures will be published in electronic version only on the ACR website.

study sponsor statements For abstracts about studies that were funded by a pharmaceutical or biotech company or other commercial enterprise, a “Role of the Study Sponsor” statement must be included (use plural “Sponsors” if more than one sponsor is listed). This statement describes for the learner the part played by the commercial entity in the conduct and reporting of the study.

Note: This applies only to commercial enterprises (e.g., pharmaceutical or biotech companies; device manufacturing

companies). It does not apply to government entities such as the NIH or its equivalent funding agencies in other countries or to public or private foundations. This statement will be published in electronic version only on the ACR website.

Institutional Review Board Affirmation An Institutional Review Board is charged with protecting the rights and welfare of people involved in research. If your research involved human subjects you will be required to check a box during the submission process to attest that you have received the appropriate IRB approval.

abstract rEVIEW aND NotIfIcatIoN After the submission deadline, completed abstracts will be peer-reviewed. “Incomplete” abstracts will not be considered. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the submission deadline – no exceptions.

Abstracts will be peer-reviewed by a subsection of the ACR Abstract Selection Committee or the ARHP Annual Meeting Program Sub-committee, according to subject categories. All reviewers are required to sign a confidentiality agreement.

• All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.

• Accepted abstracts will be selected as either a short oral presentation or a poster presentation.

• The presenting author is the point of contact for all abstract co-authors and the only author who will receive notification from the ACR. Presenting authors will be notified in August and are responsible for notifying all abstract co-authors. The late-breaking presenting authors will be notified in October and are responsible for notifying all late-breaking abstract co-authors.

An Institutional Review Board is charged with protecting the rights and welfare of people involved in research. If your research involved human subjects you will be required to check a box during the submission process to attest that you have received the appropriate IRB approval.

Visit www.ACRannualmeeting.org for more annual meeting information.

8

PrEsENtatIoN forMat Abstracts are considered for either oral presentation or poster presentation. If your abstract can only be presented as a poster, please check the appropriate box during the submission process. As English is the designated language for the meeting, the presenting author is required to speak English when presenting.

Oral Abstract Presentation Oral presentations will be 15-minute podium presentations. The presenter will have 12 minutes for presentation and 3 minutes for discussion. Oral abstract presenters will be required to bring their presentation in an electronic format to the on-site Speaker Ready Room, where they will have the opportunity to review and/or revise presentations using computers in the room. All presentations will be uploaded to a central server and sent to the appropriate meeting room on a secured intranet circuit prior to the start of the session. All slides will be checked for adherence to ACCME policies by ACR staff prior to uploading the presentation.

Oral Presentation Slide Requirements• Slide #1 must be your title slide.

• Slide #2 must be your disclosure slide. Your disclosure statement should list all commercial relationships relevant to your specific talk. Disclosures must never include the use of a trade name or a product-group message.

• Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non-company/product logos such as universities, non-profit associations and government agencies) are allowed in the body of your presentation.

• Abstracts must not contain any advertising, trade names or a product-group message.

Poster Abstract PresentationPoster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and displayed in the poster hall area from Sunday, October 27 - Tuesday, October 29. One poster session will be held each day. Presenting authors must be available at their poster from 9:00 – 11:00 am to answer questions from attendees as well as poster tour participants.

acr Poster Presenter No-show PolicyIn order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 – 11:00 am for poster presentations. Please note that the ACR will be monitoring posters during the presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees.

Posters must be mounted by 8:30 am and dismantled after 4:00 pm during the designated poster session as outlined in the abstract acceptance notification. Unclaimed posters will not be stored by the acr.

The ACR will promptly remove and recycle all posters

not picked up by 5:00 pm each day.

Poster Presentation Requirements• The backboard panel for each poster presentation board

measures 44 inches (111.76 cm) high and 90 inches (228.6 cm) wide. Posters should be printed horizontally and not exceed the size of the presentation board.

44”

90”

• Text and illustrations must be readable from distances of at least three feet. Use lightweight materials only; heavy articles are difficult to secure.

• Disclosures must never include the use of a trade name or a product-group message and must be listed once at the bottom of the poster.

• Posters may be broken down into several smaller portions, but must not exceed the size of the presentation board.

• Push pins to mount materials will be available on site.

• No audiovisual, projection or computer equipment requiring electrical power will be permitted in the poster session area.

• Poster presenters are encouraged to include a QR code on their poster that allows attendees to scan the code and view your uploaded poster as an electronic copy (see example on right):

• A copy of the accepted abstract must be included on poster or made available to attendees.

Discover the latest in Rheumatology

In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 – 11:00 am for poster presentations. Please note that the ACR will be monitoring posters during the presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees.

Visit www.ACRannualmeeting.org for more annual meeting information.

9

Guided Poster toursGuided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours.

accME standard and acr Policy regarding third-Party bias In accordance to ACCME requirements and ACR policy, abstracts selected for oral or poster presentation must be free of bias. Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non-company/product logos such as universities, non-profit associations and government agencies) are allowed in the body of your presentation. ACR requires that educational materials that are part of a CME activity, such as slides, abstracts and handouts, do not contain any advertising, trade names or a product-group message. Disclosure must never include the use of a trade name or a product-group message. For oral presentations, disclosure must be listed on the second slide of each presentation. For poster presentations, disclosure must be listed once at the bottom of the poster.

PErMIssIoNs copyright Policy The annual meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the American College of Rheumatology and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it.

The names, insignias, logos and acronyms of the ACR, the ARHP and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the American College of Rheumatology.

Media Credentialed media attend the annual meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to Meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the Exhibit Hall. Press who would like general photos of the Exhibit Hall can obtain these after the meeting from the ACR. Attendees who have questions about the ACR’s media policies should contact the public relations department at pr@rheumatology.org.

Photographs and Video recording PolicyAs a courtesy to our presenters, ACR policy does not permit photographs or recordings during educational sessions, including poster sessions. The only exception to this is for registered media, who should review their registration materials for more information.

abstract Embargo PolicyAccepted abstracts are made available to the public online in advance of the meeting and are published in a special supplement of Arthritis & Rheumatism. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 4:30 pm Pacific Time on Saturday, October 26, 2013.

NEW! The ACR will promptly remove and recycle all posters not picked up by 5:00 pm each day.

Visit www.ACRannualmeeting.org for more annual meeting information.

10

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.

abstract reprint PolicyCopyright law covers all annual meeting abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means, except as permitted under section 107 and 108 of the 1976 United States Copyright Act, without the prior permission of the publisher.

For the purposes of this statement, the term “ACR Abstracts” refers to all annual meeting abstracts as published in Arthritis & Rheumatism and posted online, including the abstracts accepted for presentation during ARHP sessions and the late-breaking category.

For the purposes of this statement, the term “ACR Posters” refers to the accepted abstracts as presented during the annual meeting. All ACR Posters are the property of the ACR or the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author.

For the purposes of this statement, the term “reproduce” includes all forms of reproduction including, but not limited to, print, electronic and photographed formats.

For the purposes of this statement, the term “presenting author” refers to the author who is designated as the individual who will present the work during the ACR annual meeting, as identified through the abstract submission process.

approval ProcessExcerpts of ACR Abstracts or ACR Abstracts in their entirety may not be reproduced without the prior written permission of the publisher. Permission requests and other permission inquiries should be addressed to:

Permissions Departmentc/o John Wiley & sons, Inc.111 river streetHoboken, NJ 07030fax: (201) 748-6008Website: www.wiley.com/go/permissions

Commercial entities seeking permission to reprint must obtain all materials from the author and/or publisher John Wiley & Sons, Inc. ACR cannot provide any materials.

Reproducing ACR Abstracts for Dissemination Prior to the Annual MeetingRequests to reproduce abstracts for dissemination prior to the annual meeting will not be approved. Per the ACR Embargo Policy, academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract online. Permission to issue a press release does not require ACR approval. However, it must comply with the ACR Embargo Policy; violation of this policy may result in the abstract being withdrawn from the meeting or other measures deemed appropriate.

reproducing acr abstracts and acr Posters for Dissemination During the Annual MeetingFollowing approval (see approval process), an exhibiting organization may:

• Disseminate copies of individual ACR Abstracts from its exhibit space. Booklets of abstracts (e.g., two or more) may not be produced.

• Disseminate information summaries (title/date/time/poster number) of ACR Abstracts from its exhibit space. Summaries may not reference company or product names. Requests for approval must be submitted in writing to abstractreprints@rheumatology.org.

Presenting authors may disseminate individual copies of their ACR Poster during their assigned poster presentation time. Dissemination must be limited to the area directly in front of their assigned poster space and may not interfere with other poster presentations.

reproducing acr abstracts and acr Posters for Dissemination After the Annual MeetingFollowing approval (see approval process), the ACR permits ACR Abstracts to be reprinted and disseminated following the annual meeting.

Discover the latest in Rheumatology

Excerpts of ACR Abstracts or ACR Abstracts in their entirety may not be reproduced without the prior written permission of the publisher.

Visit www.ACRannualmeeting.org for more annual meeting information.

11

acr abstractsBooklets of abstracts (e.g., two or more) must include the following statement on the front of the booklet:

Abstracts reprinted from the ACR/ARHP Annual Meeting held October 25 – 30, 2013. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company).

Booklets cannot contain corporate or product logos or any advertisements.

acr PostersFollowing approval from the ACR and the presenting author, copies of the ACR Posters may be reproduced.

The organization requesting permission to reproduce an ACR Poster must provide the presenting author’s written approval for review by the ACR. Requests to reproduce individual ACR Posters or booklets of Posters (e.g., two or more) must be submitted in writing to abstractreprints@rheumatology.org.

The following statement must be listed under each Poster reprint:Poster reprinted from the ACR/ARHP Annual Meeting held October 25 – 30, 2013. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company).

Use of the acr Disclosure KeyIt is suggested when referencing disclosures in the reprints, that the ACR’s disclosure key be added to provide adequate context for abstracts:

None: Nothing to disclose

1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan

2. Research grants

3. Employment (full or part-time)

4. Ownership or partnership

5. Consulting fees or other remuneration (payment)

6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson

7. Receipt of royalties

8. Speakers’ bureau

9. Other

Use of the acr’s NameThe names, insignias, logos and acronyms of the ACR, the ARHP and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the written permission of the ACR.

Use of the ACR Scientific Program ContentInformation displayed or presented at all sessions during the annual meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced or distributed without the written permission of the ACR and the presenter. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it.

PUblIcatIoN Accepted abstracts will be published in an online supplement of the October issue of Arthritis & Rheumatism, an official journal of the American College of Rheumatology. Accepted late-breaking abstracts will be published in the December issue of Arthritis & Rheumatism. All accepted abstracts will be available on the ACR annual meeting website in September.

rEVIsIoNs Proofread abstracts carefully to avoid errors prior to submission. Your abstract, if selected, will be published in print and electronic versions exactly as submitted. You may return to the online submission site to revise your abstract until Noon Eastern time on tuesday, June 25, 2013. After this date/time, the submission site will close and changes will not be made. Should a submission contain errors or the omission of contributing author names after the deadline, presenters may opt to have the abstract withdrawn.

WItHDraWals After June 25, presenting authors may submit a request to have an abstract withdrawn. All requests must be submitted via e-mail to withdrawn@rheumatology.org. Requests must include the abstract number, the title of the abstract and the presenting author’s name. The removal of the abstract from the October supplement of Arthritis & Rheumatism cannot be guaranteed if the request is received after September 17, 2013.

Visit www.ACRannualmeeting.org for more annual meeting information.

12

PrEsENtING aUtHor rEsPoNsIbIlItIEsAt the time of submission, the person submitting the abstract must identify who will be designated as the presenting author. The presenter is required to speak English when presenting, as this is the designated language for the meeting.

The presenting author will be the sole point of contact for information regarding the submission and is responsible for the following:

• Ensuring each co-author is aware of the content of the abstract and supports its data. Failure to receive approval from each co-author will result in the abstract being disqualified.

• Ensuring each co-author is aware of the disclosure requirements.

• Adhere to the Abstract Disclosure Policy and obtain disclosure information from all co-authors (see page 6).

• Forwarding abstract acceptance/rejection notifications and ACCME and ACR polices to each co-author. Co-authors should not contact the ACR for abstract status information.

• Notify each co-author of any changes to the program, as corresponded by the ACR or ARHP, in a timely manner.

• Presenting the abstract or arranging for a co-author to present the abstract if it is selected. (Only co-authors listed on the accepted abstract may serve as alternate presenting author.)

The presenting author must comply with these responsibilities or be subject to corrective action as deemed appropriate by the ACR or ARHP leadership.

• If you are the presenting author and have accepted an invitation to participate as an invited speaker or moderator and a schedule conflict is identified, it is your responsibility to appoint a co-author to present the abstract in your absence.

• Invited speaker and moderator schedules cannot be changed to accommodate abstract oral or poster presentations.

• The ACR will not collect alternate presenter information or make any presenting author corrections to printed or online publications.

Presenting Author Affirmations The ACR does not condone presentations given by an invited presenter who has not been intimately involved in the development of the data and who cannot meet the criteria for authorship. To be eligible to present, at the time of submission, the presenting authors will be required to confirm agreement with the following affirmation statements:

• I confirm I had full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis and approved the data for presentation.

• I confirm I made significant contributions to the study design, analysis or interpretation of results.

rEGIstratIoN & HoUsING Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations for the meeting. All attendees are required to register and pay the appropriate registration fees and arrange hotel accommodations.

As abstract presentation dates will be finalized in August presenting authors should plan to attend the entire meeting.

Registration and housing will open for members on Tuesday, June 4 and for non-members on Tuesday, June 18. View more registration and housing details on ACRannualmeeting.org.

2013 acr/arHP abstract catEGorIEs basIc scIENcE1. b cell biology and targets in autoimmune Disease:

B-lymphocyte differentiation, B-cell subsets, plasma cells, autoantigens, autoreactive B-cells and tissue injury.

2. biology and Pathology of bone and Joint: joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.

3. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and angiogenesis: cytokines, chemokines and their receptors; downstream signaling effects and biologic pathways; cell-cell recognition and adhesion molecules, cell-matrix interactions, matrix characteristics and properties, lymphoid organogenesis.

4. Genetics, Genomics and Proteomics: techniques, strategies and observations related to disease susceptibility and expression; bioinformatics and systems biology.

Discover the latest in Rheumatology

Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations for the meeting.

Visit www.ACRannualmeeting.org for more annual meeting information.

13

5. Innate Immunity and Rheumatic Disease: dendritic cells, antigen presentation, auto-inflammatory pathogenesis, pattern recognition receptors and their ligands, NK cells, complement and Fc receptors.

6. Pain - basic aspects: biology, mechanism and animal models of pain.

7. Pediatric Rheumatology - Pathogenesis and Genetics: pathological, genetic and other laboratory-based aspects of pediatric rheumatology conditions.

8. Rheumatoid Arthritis – Animal Models: animal models of inflammatory synovitis, mechanisms and treatment.

9. Rheumatoid Arthritis - Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis.

10. Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology: etiology and pathogenesis, including genetics, reactive arthritis and animal models.

11. systemic lupus Erythematosus - animal Models: animal models, mechanisms and treatment.

12. Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis.

13. Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics: cellular and molecular mechanisms, biomarkers.

14. t cell biology and targets in autoimmune Disease: T-lymphocyte antigens and subpopulations, cognate interactions, T-lymphocyte activation and proliferation.

clINIcal15. Antiphospholipid Syndrome: pathophysiology, presentation

and management.

16. Education: research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education including associated health training.

17. Epidemiology and Health services research: descriptive and/or analytical studies of populations as well as economic analysis; decision making.

18. Fibromyalgia, Soft Tissue Disorders and Clinical Pain syndromes: regional pain syndromes, pain mechanisms and management, local diseases of muscle, ligament and tendon, fibromyalgia.

19. Health services research, Quality Measures and Quality of care: delivery of care affecting patients with rheumatic disease.

20. Imaging of Rheumatic Diseases: radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound and computed tomography (CT).

21. Infection-related Rheumatic Disease: musculoskeletal manifestations of infectious disease, infectious arthritis and pathogenesis.

22. Metabolic and crystal arthropathies: crystal-induced arthritis, metabolic conditions including endocrine abnormalities.

23. Miscellaneous Rheumatic and Inflammatory Diseases: rheumatic manifestations and therapy of less common and even rare illnesses not included in other categories (e.g., RS3PE, reticulohistiocytosis, SAPHO).

24. Muscle Biology, Myositis and Myopathies: muscle biology, inflammatory and non-inflammatory muscle disease.

25. Orthopedics, Low Back Pain and Rehabilitation: orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine.

26. Osteoarthritis - Clinical Aspects: patient-oriented studies of osteoarthritis, including treatment, diagnosis and outcomes.

27. osteoporosis and Metabolic bone Disease - clinical aspects and Pathogenesis: patient-oriented studies of bone structure and integrity and its change in various disease states.

28. Pediatric Rheumatology - Clinical and Therapeutic Aspects: clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions.

29. Rheumatoid Arthritis - Clinical Aspects: clinical aspects of rheumatoid arthritis. Should not contain any treatment studies.

30. Rheumatoid Arthritis - Small Molecules, Biologics and Gene therapy: treatment of human rheumatoid arthritis including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only.

31. sjögren’s syndrome: pathophysiology, presentation and treatment.

32. Spondylarthropathies and Psoriatic Arthritis - Clinical aspects and treatment: small molecule and biologic therapies of spondyloarthropathies, reactive arthritis and psoriatic arthritis.

Visit www.ACRannualmeeting.org for more annual meeting information.

14

33. systemic lupus Erythematosus - clinical aspects and treatment: diagnosis, clinical manifestations, outcomes, and treatment, including new small molecules, biologics and gene therapy. Human lupus only.

34. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics: clinical aspects of these syndromes and of treatments.

35. Vasculitis: genetics, etiology, pathogenesis, polygmatic rheumatica, presentation and management.

arHP36. Clinical Practice/Patient Care: care of patients, practice

management, medication monitoring/adherence and behavioral aspects of care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

37. Education/Community Programs: patient education, professional education, community-based programs and public health programs. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

38. Epidemiology and Public Health: descriptive and analytical studies of health status and health outcomes of populations and patient groups. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

39. Health services research: health care systems and delivery economic evaluations and analysis. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

40. Pediatrics: pediatric practice and patient care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

41. Psychology/social sciences: psychology, social work, social and behavioral factors affecting patients, families and providers. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

42. Rehabilitation Sciences: physical therapy, occupational therapy, exercise programs and other rehabilitation services. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

43. research Methodology: questionnaire design, new assessment tools and methodology, new analytical techniques, and subject recruitment and retention. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

ACR LATE-BREAKING ABSTRACTS Eligibility The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the Tuesday, June 25, 2013 abstract submission deadline. An abstract is ineligible for consideration if it reports work that has been accepted prior to the ACR late-breaking submission deadline of October 1, 2013, for publication as a manuscript.

This category is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the general abstract submission deadline of June 25. Please note the following:

• Late-breaking abstracts may deal with either basic or clinical research.

• Case reports are not considered appropriate and will not be reviewed.

• Abstracts should present data that is ground-breaking, innovative and has a high impact factor.

• Abstracts submitted for the late-breaking category cannot be submitted to any other category.

Discover the latest in Rheumatology

Late-breaking abstracts should present data that is ground-breaking, innovative and has a high impact factor.

Visit www.ACRannualmeeting.org for more annual meeting information.

15

In order for an abstract to be considered for late-breaking presentation, the presenting author must:

• Explain in 50 words or less why the abstract is being submitted to the late-breaking category and why it is especially newsworthy and deserving of consideration. Stating the “results are just now available” is not a sufficient explanation.

• Indicate a primary research category, (e.g., Basic, Clinical, Observational, Interventional, etc.)

• Identify the trial phase, if the abstract reports results of a clinical trial not yet approved by a regulatory agency.

SUBMITTING A LATE-BREAKING abstract Abstracts must be submitted online at ACRannualmeeting.org. The late-breaking abstract submission site will open on Monday, September 16 and close on Tuesday, October 1 at Noon Eastern Time. Submitters will not have access to the submission site after the submission deadline.

late-breaking abstract Processing fee A $130 processing fee (in U.S. funds) must accompany each late-breaking abstract. The ACR accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees are non-refundable – no exceptions.

Presentation Format Late-breaking abstracts will be selected for oral or poster presentations and submitters should be prepared to present in either format. As English is the designated language for the meeting, the presenting author is required to speak English when presenting.

late-breaking abstract Withdrawals After October 1, presenting authors may submit a request to have an abstract withdrawn. All requests must be submitted via e-mail to withdrawn@rheumatology.org. Request must include the control number of the abstract, the title of the abstract and the presenting author’s name. The removal of the abstract from the December issue of Arthritis & Rheumatism cannot be guaranteed, if the request is received after October 25.

late-breaking abstract No-show PolicySubmission of a late-breaking abstract constitutes a commitment by the presenting author to present their work at the annual meeting in San Diego. No-show presenters will be reported to the Annual Meeting Planning Committee and may affect future abstract submission opportunities.

Late-breaking abstracts are also subject to the ACR’s Embargo Policy.

See you in San Diego!

2013 a c r /a r H P a N N U a l M E E t I N G I M P o r ta N t D at E s abstract DeadlinesAbstract submission site opens ............................................................................................ Monday, May 6Abstract submission site closes .......................................................................................... Tuesday, June 25Late-breaking abstract submission site opens ..........................................................Monday, September 16Late-breaking abstract submission site closes .................................................................Tuesday, October 1

Registration and HousingMember registration and housing opens ........................................................................ Wednesday, June 4Non-Member registration and housing opens ..............................................................Wednesday, June 18Last day to register at early bird rates ................................................................................ Friday, August 30Last day to register at reduced advanced registration rates ............................................ Friday, October 11

2013 ACR/ARHP Annual Meeting Pre-conference Courses............................................................... Friday, October 25 - Saturday, October 26Opening Lecture and Awards, Opening Reception ...................................................... Saturday, October 26Scientific Sessions ................................................................. Sunday, October 27 - Wednesday, October 30

the latest in RheumatologyDiscover

S a n D i e g o ‘ 1 3

w w w. A C R a n n u a l m e e t i n g . o r g